I speak with infusion leaders every day—from major health systems to independent infusion practices—and the same challenge comes up time and again: ...

Novartis's bid to expand its $2.1 million-per-patient gene therapy Zolgensma to more spinal muscular atrophy patients faces a possible delay after U.S. regulators requested another study in older ...

Novartis said new interim data from an ongoing phase clinical trial for its $2.1 million-per-patient gene therapy Zolgensma showed spinal muscular atrophy patients experienced significant therapeutic ...

An expert discusses efforts to improve the tolerability and delivery of the MARIPOSA regimen, highlighting subcutaneous amivantamab from the Paloma studies and proactive skin care strategies from the ...

The most innovative, influential, and informative listens in the history of the medium. These podcasts reflect the depth, breadth, and possibility of the medium at its best. 2 Dope Queens Unfiltered ...

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who ...

The apitegromab approval process reminded guest writer Joanna Buoniconti of lessons about keeping hope alive while protecting ...